JUL 07, 2020 9:00 AM PDT

Enhancing risk stratification in early colon cancer with TNM-I (Immune) staging: focus on stage II T4N0 patients

Sponsored by: HalioDx
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Director, Inserm, Cordeliers Research Center, Paris, France
    Biography
      Jérôme Galon is director of research at INSERM (French NIH) and head of the laboratory of Integrative Cancer Immunology, in Paris, France. He is also associate director and co-founder of the European Academy of Tumor Immunology (EATI), board member of the Society for Immunotherapy of Cancer (SITC), co-founder of HalioDx company and the chairman of its scientific council. His work on the comprehensive analysis of the tumor microenvironment led to the concept of cancer immune contexture.

      Jérôme Galon pioneered Immunoscore and is the principal investigator of the Worldwide Immunoscore Consortium. He has been consultant and/or served on the scientific advisory board of 28 biotech and pharmaceutical companies. His contributions have been recognized with numerous awards, including the William B Coley Award, USA (2010), the prestigious European Patent Office (EPO, EU) as European Inventor 2019 for his Immunoscore®, the Senior Research Prize Jean Valade from the Fondation de France (2020) and on January 1st 2020, he was appointed Knight of the Legion of Honour by presidential decree.
    • Medical Science Director, HalioDx Inc.
      Biography
        Dr. Poage joined HalioDx in 2019, to coincide with the launch of the Immunoscore assay for early stage colon cancer in the US and to build the Medical Affairs/Market Access functions. Prior to HalioDx, he was a medical scientist at Biotheranostics, where he conducted collaborative clinical research studies and brought awareness to unmet needs in medical oncology. His past work focused on basic biology and biomarker-driven research in women's cancers while a Laboratory Director in the Department of Clinical Investigations at the Brooke Army Medical Center in San Antonio. During his time in fellowship at the University of Texas - MD Anderson Cancer Center in Houston, Texas he also focused on biomarker research in women's cancers. Dr. Poage holds a B.A. in Biochemistry from Colby College and a Ph.D. in Molecular Pharmacology, Physiology, and Biotechnology from Brown University.

      Abstract

      DATE:  July 07, 2020

      TIME:   9:00 am PDT

       

      The widely used TNM staging system is poorly predictive of response to adjuvant chemotherapy in Stage II and III colon cancer. As a result, there is overutilization of adjuvant chemotherapy in some patients at low risk for recurrence, and underutilization in patients at high risk for recurrence. There is a strong unmet need for a better prognostic and predictive tool to personalize treatment decisions in colorectal cancer.

      The World Health Organization (WHO) recently introduced immune response as an essential and desirable diagnostic criterion for CRC alongside standard histological parameters, indicating that assessment of immune response is now an essential complement to standard staging procedures. Immunoscore® is the first consensus, standardized and commercially available test clinically validated for this assessment.

      This webinar will focus on our latest data presented at ASCO 2020 and ESMO-GI 2020. First, prognostic performance on T4N0 colon cancer patients will be presented, showing that Immunoscore® identifies which patients have a lower risk of recurrence who might be spared adjuvant chemotherapy. Secondly, use of TNM-Immune (TNM-I) classification system to determine treatment benefit in selected patients will be discussed.

       

      Learning Objectives:

      • Understand the value of Immunoscore® on top of standard tools for early stage Colon Cancer patients
      • Evaluate impact of Immunoscore® on treatment decisions for T4N0 Colon Cancer patients
      • Outline the utility of a TNM-I approach for Colon Cancer risk assessment

       

      Webinars will be available for unlimited on-demand viewing after live event.

       

      LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.


      Show Resources
      You May Also Like
      MAY 11, 2021 10:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      MAY 11, 2021 10:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
      JUN 09, 2021 7:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      JUN 09, 2021 7:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
      DEC 02, 2020 8:00 AM PST
      C.E. CREDITS
      DEC 02, 2020 8:00 AM PST
      DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
      NOV 18, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 18, 2020 8:00 AM PST
      DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
      OCT 29, 2020 6:00 AM PDT
      C.E. CREDITS
      OCT 29, 2020 6:00 AM PDT
      Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
      APR 01, 2021 8:00 AM PDT
      C.E. CREDITS
      APR 01, 2021 8:00 AM PDT
      Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
      Loading Comments...
      Show Resources
      Attendees
      • See more